REGENXBIO Inc. (RGNX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RGNX SEC filings page.
REGENXBIO Inc. (RGNX) reported $174.5M in revenue over the twelve months to Jun 30, 2026, up 12.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
REGENXBIO remains development-led: revenue rebounded, but R&D and financing needs still outweigh internally generated cash.
Operating cash outflow narrowed to$124M from$173M in FY2024, showing that FY2025's revenue rebound improved cash conversion rather than merely changing the reported loss. Yet R&D reached$228M against revenue of$170M , so commercial receipts still did not fund the development program.
The loss structure is development-heavy, not a conventional margin story: R&D was
The balance sheet absorbed the rebound unevenly: liabilities rose to
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of REGENXBIO Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
REGENXBIO Inc. held $240.9M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $124.0M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and REGENXBIO Inc. scores 49/100 among other emerging companies.
REGENXBIO Inc. had 52M shares outstanding at the end of fiscal year 2025, against 50M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and REGENXBIO Inc. scores 53/100 among other emerging companies.
REGENXBIO Inc. spent $228.3M on research and development in fiscal year 2025, which was 68.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and REGENXBIO Inc. scores 90/100 among other emerging companies.
REGENXBIO Inc. reported revenue of $170.4M in fiscal year 2025, against $83.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and REGENXBIO Inc. scores 75/100 among other emerging companies.
REGENXBIO Inc.'s operations used $124.0M of cash in fiscal year 2025, against $173.1M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and REGENXBIO Inc. scores 68/100 among other emerging companies.
REGENXBIO Inc.'s cash, cash equivalents and investments came to $240.9M at the end of fiscal year 2025, against $350.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and REGENXBIO Inc. scores 50/100 among other emerging companies.
REGENXBIO Inc. scores -3.01, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($490.5M) relative to total liabilities ($350.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
REGENXBIO Inc. passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
REGENXBIO Inc. reported a net loss of $193.9M while operations used $124.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
REGENXBIO Inc. reported an operating loss of $161.2M against $45.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
REGENXBIO Inc. generated $108.0M in revenue in Q2 2026. This represents an increase of 405.7% from the same quarter a year earlier. Against the prior quarter it is up 1589.6%.
REGENXBIO Inc.'s EBITDA was $33.0M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 155.6% from the same quarter a year earlier. Against the prior quarter it is up 141.5%.
REGENXBIO Inc. reported $22.7M in net income in Q2 2026. This represents an increase of 132.0% from the same quarter a year earlier. Against the prior quarter it is up 125.2%.
REGENXBIO Inc. earned $0.43 per diluted share (EPS) in Q2 2026. This represents an increase of 131.2% from the same quarter a year earlier. Against the prior quarter it is up 125.0%.
Cash & Balance Sheet
REGENXBIO Inc. recorded an outflow of $63.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 26.7% from the same quarter a year earlier. Against the prior quarter it is up 18.6%.
REGENXBIO Inc. held $36.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
REGENXBIO Inc.'s operating margin was 27.1% in Q2 2026, reflecting core business profitability. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
REGENXBIO Inc.'s net profit margin was 21.0% in Q2 2026, showing the share of revenue converted to profit. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
REGENXBIO Inc.'s ROE was 31.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 64.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 458.8 percentage points.
Not reported for Q2 2026.
Capital Allocation
REGENXBIO Inc. invested $56.1M in research and development in Q2 2026. This represents a decrease of 5.7% from the same quarter a year earlier. Against the prior quarter it is down 2.2%.
REGENXBIO Inc. invested $760K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 94.4% from the same quarter a year earlier. Against the prior quarter it is down 38.5%.
Not reported for Q2 2026.
RGNX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $108.0M+405.7% | $6.4M-92.8% | $30.3M+43.0% | $29.7M+22.9% | $21.4M-4.2% | $89.0M+469.8% | $21.2M-4.5% | $24.2M-16.3% |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | $6.3M-43.8% | $12.4M0.0% |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | $14.9M+35.7% | $11.8M-28.5% |
| R&D Expenses | $56.1M-5.7% | $57.3M+8.0% | $59.6M+18.3% | $56.1M+3.1% | $59.5M+21.8% | $53.1M-3.2% | $50.4M-9.5% | $54.4M-6.5% |
| SG&A Expenses | $21.6M+8.7% | $21.3M+4.7% | $22.4M+11.6% | $20.3M+4.3% | $19.9M+5.5% | $20.3M+11.2% | $20.1M+5.1% | $19.4M-15.9% |
| Operating Income | $29.3M+146.2% | -$83.4M-787.4% | -$57.6M-12.2% | -$52.4M+15.6% | -$63.3M-12.9% | $12.1M+119.0% | -$51.4M+19.6% | -$62.1M+4.4% |
| EBITDA | $33.0M+155.6% | -$79.5M-594.4% | -$53.8M-13.6% | -$48.5M+16.5% | -$59.4M-14.2% | $16.1M+126.9% | -$47.3M+20.5% | -$58.1M+4.1% |
| Interest Expense | $7.8M-29.1% | $8.7M+1.6% | $12.3M+30.4% | $13.2M+1506.0% | $11.0M+2348.3% | $8.6M+334.4% | $9.4M+590.9% | $820K-49.5% |
| Net Income | $22.7M+132.0% | -$90.1M-1580.4% | -$67.1M-31.2% | -$61.9M-3.9% | -$70.9M-33.7% | $6.1M+109.6% | -$51.2M+18.6% | -$59.6M+3.7% |
| EPS (Basic) | $0.43+131.2% | -$1.72-1533.3% | -$1.30-30.0% | -$1.20-2.6% | -$1.38-31.4% | $0.12+108.7% | -$1.00+29.6% | -$1.17+17.0% |
| EPS (Diluted) | $0.43+131.2% | -$1.72-1533.3% | -$1.30-30.0% | -$1.20-2.6% | -$1.38-31.4% | $0.12+108.7% | -$1.00+29.6% | -$1.17+17.0% |
| Diluted Shares (Avg) | 53M+3.0% | 52M+1.9% | N/A | 52M+1.8% | 51M+1.7% | 51M+12.5% | N/A | 51M+15.6% |
Not reported in any period shown, so not listed: Income Tax.
RGNX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $386.6M-33.5% | $341.9M-30.4% | $453.0M-2.8% | $525.2M+1.2% | $581.0M+2.0% | $490.9M-22.0% | $466.0M-18.8% | $519.1M-18.1% |
| Current Assets | $236.2M-36.8% | $186.5M-40.5% | $281.3M+1.2% | $332.0M+5.9% | $373.8M+7.8% | $313.2M-20.8% | $278.0M-17.0% | $313.4M-14.3% |
| Cash & Equivalents | $36.5M-54.1% | $15.2M-88.3% | $34.5M-40.1% | $58.8M+3.9% | $79.6M+37.7% | $130.1M+15.2% | $57.5M+66.6% | $56.6M+6.7% |
| Short-Term Investments | $69.0M-71.7% | $135.3M-1.8% | $195.6M+10.4% | $215.4M+8.3% | $243.7M+4.8% | $137.8M-39.0% | $177.2M-26.4% | $198.8M-20.1% |
| Accounts Receivable | $106.8M+428.5% | $10.0M-44.8% | $26.4M+28.8% | $25.3M+7.4% | $20.2M-11.4% | $18.2M+14.9% | $20.5M-17.4% | $23.6M-15.8% |
| Long-Term Investments | $0-100.0% | $0-100.0% | $10.8M+6.0% | $27.8M+20.5% | $40.3M+9.1% | $4.9M-88.4% | $10.2M-73.8% | $23.1M-63.1% |
| Total Liabilities | $314.9M-14.3% | $320.8M+48.0% | $350.3M+69.8% | $363.8M+67.1% | $367.3M+66.1% | $216.7M-9.1% | $206.3M-21.3% | $217.7M-19.6% |
| Current Liabilities | $82.6M-30.9% | $71.1M-33.4% | $118.1M+14.4% | $124.6M+21.3% | $119.5M+21.6% | $106.7M-3.1% | $103.2M-20.8% | $102.7M-19.3% |
| Non-Current Liabilities | $232.2M-6.3% | $249.7M+127.0% | $232.2M+125.1% | $239.2M+108.0% | $247.8M+101.7% | $110.0M-14.3% | $103.1M-21.8% | $115.0M-19.8% |
| Total Equity | $71.8M-66.4% | $21.1M-92.3% | $102.7M-60.4% | $161.5M-46.4% | $213.7M-38.6% | $274.2M-29.8% | $259.7M-16.7% | $301.4M-17.0% |
| Retained Earnings | -$1.2B-19.7% | -$1.2B-31.3% | -$1.1B-20.8% | -$1.1B-20.2% | -$996.9M-21.4% | -$926.1M-20.5% | -$932.1M-32.2% | -$881.0M-37.2% |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
RGNX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$62.2M-26.1% | -$76.2M-326.5% | -$52.3M-65.3% | -$56.0M-38.0% | -$49.3M-8.5% | $33.6M+160.6% | -$31.6M+22.4% | -$40.5M+17.9% |
| Depreciation & Amortization | $3.8M-3.8% | $3.9M-2.5% | $3.9M-3.8% | $3.9M-1.9% | $3.9M-3.6% | $4.0M-5.4% | $4.0M-7.2% | $4.0M-9.4% |
| Stock-Based Compensation | $9.1M+4.6% | $8.6M+0.9% | N/A | $9.0M-9.0% | $8.7M-8.3% | $8.5M-11.1% | N/A | $9.9M-3.3% |
| Capital Expenditures | $760K+94.4% | $1.2M+20.6% | $508K-52.9% | $491K+50.6% | $391K-17.5% | $1.0M+83.8% | $1.1M-4.2% | $326K-77.3% |
| Free Cash Flow | -$63.0M-26.7% | -$77.4M-337.5% | -$52.8M-61.4% | -$56.5M-38.1% | -$49.7M-8.2% | $32.6M+158.2% | -$32.7M+21.9% | -$40.9M+19.6% |
| Investing Cash Flow | $65.9M+146.9% | $70.6M+57.8% | $37.5M-6.8% | $42.3M-15.9% | -$140.4M-52301.5% | $44.7M+239.4% | $40.3M+18.5% | $50.3M+30.0% |
| Financing Cash Flow | $17.6M-87.4% | -$13.6M-135.4% | -$9.6M-23.8% | -$7.1M+34.8% | $139.2M+1574.1% | -$5.8M-104.8% | -$7.7M+35.3% | -$10.9M-126.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
RGNX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | 70.2%+20.8pp | 48.8%-8.4pp |
| Operating Margin | 27.1% | -1304.0% | -190.0% | -176.3% | -296.3% | 13.6% | -242.1% | -256.6% |
| Net Margin | 21.0% | -1408.6% | -221.3% | -208.3% | -331.8% | 6.8% | -241.3% | -246.3% |
| Return on Equity | 31.6%+64.8pp | -427.1%-429.4pp | -65.4%-45.6pp | -38.4%-18.6pp | -33.2%-17.9pp | 2.2%+18.4pp | -19.7%+0.5pp | -19.8%-2.7pp |
| Return on Assets | 5.9%+18.1pp | -26.3%-27.6pp | -14.8%-3.8pp | -11.8%-0.3pp | -12.2%-2.9pp | 1.2%+11.3pp | -11.0%0.0pp | -11.5%-1.7pp |
| Current Ratio | 2.86-0.3x | 2.62-0.3x | 2.38-0.3x | 2.66-0.4x | 3.13-0.4x | 2.93-0.7x | 2.69+0.1x | 3.05+0.2x |
| Debt-to-Equity | 4.39+2.7x | 15.22+14.4x | 3.41+2.6x | 2.25+1.5x | 1.72+1.1x | 0.79+0.2x | 0.790.0x | 0.720.0x |
| Asset Turnover | 0.28+0.2x | 0.02-0.2x | 0.070.0x | 0.060.0x | 0.040.0x | 0.18+0.2x | 0.050.0x | 0.050.0x |
| FCF Margin | -58.3% | -1211.0% | -174.0% | -189.9% | -232.8% | 36.6% | -154.2% | -168.9% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| REGENXBIO Inc. RGNX | FY2025 | $170.4M | -$193.9M | N/A | $490.5M | 64/100 |
| Arcturus Therapeutics Holdings Inc. ARCT | FY2025 | $82.0M | -$65.8M | -80.2% | $370.4M | 54/100 |
| Replimune Group, Inc. REPL | FY2026 | N/A | -$313.9M | N/A | $1.2B | — |
| Kodiak Sciences Inc KOD | FY2025 | N/A | -$230.0M | N/A | $5.9B | — |
| aTyr Pharma, Inc. ATYR | FY2025 | $190K | -$74.1M | N/A | $28.2M | — |
| Bicycle Therapeutics plc BCYC | FY2025 | $72.6M | -$219.0M | N/A | $236.6M | 60/100 |
Where REGENXBIO Inc. Ranks
Frequently Asked Questions
What is REGENXBIO Inc.'s annual revenue?
REGENXBIO Inc. (RGNX) reported $170.4M in total revenue for fiscal year 2025. This represents a 104.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is REGENXBIO Inc.'s revenue growing?
REGENXBIO Inc. (RGNX) revenue grew by 104.5% year-over-year, from $83.3M to $170.4M in fiscal year 2025.
Is REGENXBIO Inc. profitable?
No, REGENXBIO Inc. (RGNX) reported a net income of -$193.9M in fiscal year 2025.
What is REGENXBIO Inc.'s EBITDA?
REGENXBIO Inc. (RGNX) had EBITDA of -$145.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is REGENXBIO Inc.'s operating margin?
REGENXBIO Inc. (RGNX) had an operating margin of -94.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is REGENXBIO Inc.'s return on equity (ROE)?
REGENXBIO Inc. (RGNX) has a return on equity of -188.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is REGENXBIO Inc.'s free cash flow?
REGENXBIO Inc. (RGNX) recorded an outflow of $126.4M in free cash flow during fiscal year 2025. This represents a 28.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is REGENXBIO Inc.'s operating cash flow?
REGENXBIO Inc. (RGNX) recorded an outflow of $124.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are REGENXBIO Inc.'s total assets?
REGENXBIO Inc. (RGNX) had $453.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are REGENXBIO Inc.'s capital expenditures?
REGENXBIO Inc. (RGNX) invested $2.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does REGENXBIO Inc. spend on research and development?
REGENXBIO Inc. (RGNX) invested $228.3M in research and development during fiscal year 2025.
What is REGENXBIO Inc.'s current ratio?
REGENXBIO Inc. (RGNX) had a current ratio of 2.38 as of fiscal year 2025, which is generally considered healthy.
What is REGENXBIO Inc.'s debt-to-equity ratio?
REGENXBIO Inc. (RGNX) had a debt-to-equity ratio of 3.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is REGENXBIO Inc.'s return on assets (ROA)?
REGENXBIO Inc. (RGNX) had a return on assets of -42.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is REGENXBIO Inc.'s P/E ratio?
REGENXBIO Inc. (RGNX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $490.5M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is REGENXBIO Inc.'s price-to-sales ratio?
REGENXBIO Inc. (RGNX) trades at 2.8x sales, its market capitalization divided by revenue of $174.5M revenue, trailing 12 months to June 30, 2026. The market capitalization is $490.5M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does REGENXBIO Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, REGENXBIO Inc. (RGNX) held $240.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $124.0M over that year. Dividing the one by the other, the reported balance equals about 23 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is REGENXBIO Inc.'s Altman Z-Score?
REGENXBIO Inc. (RGNX) has an Altman Z-Score of -3.01, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is REGENXBIO Inc.'s Piotroski F-Score?
REGENXBIO Inc. (RGNX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are REGENXBIO Inc.'s earnings high quality?
REGENXBIO Inc. (RGNX) reported a net loss of $193.9M while operations used $124.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can REGENXBIO Inc. cover its interest payments?
REGENXBIO Inc. (RGNX) reported an operating loss of $161.2M against $45.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is REGENXBIO Inc.?
REGENXBIO Inc. (RGNX) scores 64 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.